Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28656077 | 0.84 | CYP19A1 (0.49) | CHRM3CYP19A1CHRM2LMNACYP2D6 | |
| SCHEMBL28559393 | 0.81 | CYP19A1 (0.44) | CHRM3CYP19A1TAAR1 | |
| SCHEMBL28647858 | 0.79 | CHRM3 (0.46) | CHRM3CYP19A1CHRM2LMNACYP2D6 | |
| Hydrochloric Acid SCHEMBL29006951 | 0.79 | CHRM3 (0.44) | CHRM3SMN1; SMN2HIF1ASLC6A2TAAR1 | |
| Hydrochloric Acid SCHEMBL29006948 | 0.79 | CHRM3 (0.44) | CHRM3SMN1; SMN2HIF1ASLC6A2TAAR1 | |
| SCHEMBL28658742 | 0.77 | CYP19A1 (0.42) | CHRM3CYP19A1CHRM2LMNACYP2D6 | |
| SCHEMBL1632109 | 0.77 | SLC6A2 (0.52) | SMN1; SMN2HIF1ASLC6A2TAAR1BLM | |
| SCHEMBL8745476 | 0.77 | SLC6A2 (0.52) | SMN1; SMN2HIF1ASLC6A2TAAR1BLM | |
| SCHEMBL5180745 | 0.77 | SLC6A2 (0.52) | SMN1; SMN2HIF1ASLC6A2TAAR1BLM | |
| SCHEMBL28570731 | 0.76 | CYP19A1 (0.41) | CHRM3CYP19A1CHRM2LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| EP-2401257-A1 | ENZYME INHIBITORS | Chroma Therapeutics Ltd. (GB) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097586-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097586-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303576-A1 | ENZYME INHIBITORS | HDAC1, HDAC4, HDAC3 | CHRM3 479/4885CYP19A1 387/4885SMN1; SMN2 2429/4885 |
| US-20140155439-A1 | ENZYME INHIBITORS | HDAC4, HDAC1, HDAC3 | CHRM3 659/4885CYP19A1 577/4885SMN1; SMN2 2931/4885 |
| US-20120149736-A1 | ENZYME INHIBITORS | HAT1, HDAC1, NAT1 | CHRM3 633/4885CYP19A1 534/4885SMN1; SMN2 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.